Secarna Pharmaceuticals GmbH & Co. KG, a leader in the discovery and development of next-generation oligonucleotide therapeutics, has announced the signing of a research and option agreement with a portfolio company of Curie.Bio. The agreement establishes a scientific and strategic collaboration aimed at accelerating the development of novel oligonucleotide-based therapies.

As part of the collaboration, Secarna will apply its proprietary, AI-driven OligoCreator platform to design and develop oligonucleotide candidates targeting an undisclosed disease pathway. The alliance is intended to fast-track therapeutic discovery by combining Secarna’s advanced platform capabilities with the disease-specific expertise of the Curie.Bio-backed company. Under the terms of the agreement, Secarna will receive a technology access fee, research funding, and warrants to acquire equity in the portfolio company upon reaching defined success milestones.

The OligoCreator platform integrates a wide array of delivery technologies with proprietary safety and efficacy testing systems. This enables the rapid identification and characterization of highly specific, safe, and effective oligonucleotide therapeutics, reinforcing Secarna’s position as a key innovator in the field and advancing its mission to address diseases that remain unresponsive to conventional treatment options.

Commenting on the collaboration, Dr. Konstantin Petropoulos, Chief Executive Officer of Secarna Pharmaceuticals, noted: Our AI-powered OligoCreator platform is engineered to deliver targeted, safe, and efficacious oligonucleotide therapies with speed and precision. We are pleased to partner with Curie.Bio and their portfolio company, who share our commitment to advancing breakthrough science. Emerging biotech companies often possess deep insights into disease mechanisms but may lack the infrastructure or platforms necessary to accelerate drug discovery. By joining forces and leveraging Curie.Bio’s expertise in drug development, we aim to bridge that gap and unlock new therapeutic opportunities for patients with challenging conditions.

Source: https://www.secarna.com/news-events/news/secarna-pharmaceuticals-and-curie-bio-portfolio-company-enter-into-research-and-option-agreement